CDC Shortens Recommended Period Before Pfizer Booster to Five Months
Posts published by “Robert Langreth”
Biogen Inc. fought back against criticism of the unusual circumstances that led to the U.S. approval of its Alzheimer’s drug Aduhelm, saying in an open letter it has been the subject of “extensive misinformation and misunderstanding.”
Here’s the latest news: